A digital therapeutic developed by Vicore Pharma and Alex Therapeutics has been shown to reduce the psychological burden of living with pulmonary fibrosis (PF) in a pivota
Now in its 7th year, this is the undisputed (and only!) meeting dedicated to harnessing emerging biological understanding, employing novel preclinical models to cement translational confide
BenevolentAI has discovered a second novel target for idiopathic pulmonary fibrosis (IPF), which AstraZeneca has added to its drug development portfolio, resulting in a milestone payment to the Lon
Privately-held biotech Galecto has raised $64m with an equity funding round to further research into treatments for drugs including a potential inhaled idiopathic pulmonary fibrosis (IPF) m
Endeavor BioMedicines has completed a third-round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.